Antibody Drug Conjugates Market To Witness Huge Growth By 2030

The Market Statsville Group (MSG) publishes the new report on the "Antibody Drug Conjugates Market by Product Type (Adcetris, Kadcyla, and Other Product Type), by Technology (Cleavable Linker and Non-Cleavable Linker), by Target Type (CD30 Antibodies, HER2 Antibodies, and Other Target Types), by Application (Breast Cancer, Cancer, Lung Cancer, Skin Cancer, Blood Cancer, Brain Tumor, and Other Applications), by End-Users (Hospitals and Speciality Cancer Centers, and Other End Users), by Region - Global Share and Forecast to 2030". The global antibody-drug conjugates market size is expected to grow from USD 4,990.5 million in 2021 to USD 33,140.3 million by 2030, at a CAGR of 26.7% during the forecast period. Cancer is a disease in which some of the body's cells grow uncontrollably and spread to other parts of the body. It can start anywhere in the human body. Cancerous tumors can spread into or invade nearby tissues and travel to distant places in the body. According to the International Agency for Research on Cancer (IARC) Statistics, of December 2020, it was estimated that globally 1 in 5 people develop cancer during their lifetime. The same source also suggests that more than 50 million people live within five years of a past cancer diagnosis. Thus, with the high probability of people suffering or being diagnosed with cancer, the need for treatment is increasing tremendously. Thus, boosting the growth of the studied market. Thus, with the growing incidence of cancer globally, effective treatment is highly needed to save the population. Hence, the market is expected to show lucrative growth over the forecast period.

Global Antibody Drug Conjugates Market Segmentation

The overall antibody-drug conjugates market has been segmented into the product, technology, target, application, end-users, and region.

By Product Type (Adcetris, Kadcyla, and Other Product Type)
By Technology (Cleavable Linker and Non-Cleavable Linker)
By Target Type (CD30 Antibodies, HER2 Antibodies, and Other Target Types)
By Application (Blood Cancer, Cancer, Lung Cancer, Breast Cancer, Skin Cancer, Brain Tumor, and Other Applications)
By End-Users (Hospitals and Speciality Cancer Centers, and Other End Users)
By Region (US, Canada, Mexico, UK, Germany, France, Italy, Spain, China, Japan, India, South Korea, Southeast Asia, Australia, Saudi Arabia, UAE, South Africa, Qatar, Nigeria, Israel, Brazil, Argentina, Peru)
Cleavable Linker, by technology, is estimated to hold the largest market share during the forecast period

The global antibody drug conjugates market is segmented into Cleavable and Non-Cleavable Linker based on the technology. In 2021, the Cleavable Linker segment generated the highest revenue of 55% of the global antibody-drug conjugates market in 2021, and it is expected to register a significant CAGR from 2022 to 2030. Cleavable linkers play a major role in the success of antidrug conjugates (ADCs). They use the natural structures of tumor cells to release by selecting cytotoxins from ADCs. The protease sensory system utilizes the major proteases found in tumor cell lysosomes to detect and attach certain peptide sequences to a link. Acid-sensitive strategy using lower pH of the endosome (pH = 5-6) and lysosome (pH = 4.8) chambers versus cytoplasm (pH = 7.4) to initiate hydrolysis of the acid-labile group within the link, such as hydrazone. The third release strategy uses more concentration of intracellular glutathione than plasma. Therefore, the disulfide-containing link releases cytotoxins after glutathione depletion. Cleavable linkers represent the major class of ADC linkers. As their name indicates, the small molecules cleave in response to specific chemical signals. The growing research on these linkers and the launches and advances in this field is expected to boost the segment growth.

Don't miss out on business opportunities in Antibody Drug Conjugates Market. Speak to our research analyst and gain crucial market insights to grow your business.

North America accounts for the largest market share in antibody-drug conjugates market 2021

Based on the regions, the global antibody-drug conjugates market has been segmented across North America, Asia-Pacific, Europe, South America, and the Middle East & Africa. In 2021, North America accounted for the highest market share of 44.7% in the global antibody-drug conjugates market and was anticipated to maintain its dominance throughout the forecast period. The robust growth of the healthcare sector in the United States, increasing incidences of cancer, the growing geriatric population, and the increase in product launches that are leading to the rising use of antibody drug conjugates, along with greater initiatives and investments towards advanced healthcare solutions involving cancer treatment, is expected to boost the market growth.

Additionally, many developments are taking place in the United States, including product launches and approvals, partnerships, collaborations, mergers, and acquisitions in the market for antibody-drug conjugates. For instance, in April 2021, ADC Therapeutics announced that it had received authorization from the United States Food and Drug Administration for its CD19-targeted antibody-drug conjugate called ZYNLONTA. The drug was approved as a third-line therapy for patients with relapsed or refractory diffuse large B-cell lymphoma. Approvals such as these are expected to boost market growth.

This research report includes a study on the development and marketing strategies, along with a study on the product portfolios and winning strategies of the leading companies operating in the antibody-drug conjugates market. It also consists of the profiles of leading companies such as F. Hoffman-La Roche Ltd., Pfizer, Inc., Seattle Genetics Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Genentech Inc., Immunogen Inc., Progenics Pharmaceuticals Inc., Immunomedics, Inc., Agensys, Inc., Concortis Biotherapeutics, Celldex Therapeutics Inc., Sanofi S.A., Bayer Healthcare Pharmaceuticals., and Synthon Holding B.V.

Browse complete report: https://www.marketstatsville.com/antibody-drug-conjugates-market

About Market Statsville Group

Market Statsville Group (MSG) is a business research and consulting platform of Statsville Consulting Private Limited, based in Oklahoma, USA. MSG is the leading market research and strategy builder with the depth and breadth of solutions that perfectly suit your every need. MSG provides solutions in a wide range of industry verticals in market sizing, analysis, and intelligent business insights. MSG has experienced research analysts who are proficient at digging deep and providing various customizable data that help you make decisions with clarity, confidence, and impact. Furthermore, Market Statsville Group already benefited more than 1,000 companies each year for their revenue planning. It helped them take their disruptions/innovations early to the market by providing them research ahead of the curve.

MSG has an entire repository of research reports on more than 1,000 niche industries, 3,000 high-growth potentials markets, 5,000 data sets, and more than 12,000 company profiles.

Eric Martin
416, East standsberry street,
Perkins, Oklahoma 74059, US
USA: +1-580-205-2707 | India: +91-702-496-8807
Email: sales@marketstatsville.com
MSG Blog https://marketstatsvilleblogs.com/
Web: https://marketstatsville.com/

Market Statsville Group (MSG) partners with companies and society to confront their essential risks and challenges to capture the enormous opportunities for them. MSG initiated its work in 2017, and since then, the brand is moving to become a pioneer in business advisory and market research services.

This release was published on openPR.